^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Thymidine phosphorylase inhibitor

    Related drugs:
    23h
    FRUQUITAS: Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma (clinicaltrials.gov)
    P3, N=324, Recruiting, Federation Francophone de Cancerologie Digestive | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN18 (Claudin 18)
    |
    Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    3d
    ERASE-CRC: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients (clinicaltrials.gov)
    P2, N=477, Suspended, Gruppo Oncologico del Nord-Ovest | Trial completion date: Dec 2027 --> Dec 2029 | Recruiting --> Suspended | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial suspension • Trial primary completion date • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    RAS wild-type
    |
    Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • Tukysa (tucatinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium
    4d
    ROMANCE - GOIM: ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Gruppo Oncologico Italia Meridionale
    New P2 trial • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
    |
    BRAF V600E • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • irinotecan • Lonsurf (trifluridine/tipiracil)
    5d
    A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer. (PubMed, Discov Oncol)
    In this retrospective, real-world study, the two regimens demonstrated comparable disease control, and the bi-weekly regimen appeared to be better tolerated, representing a reasonable potential alternative. Nevertheless, these findings should be interpreted as exploratory, and future prospective studies are warranted.
    Journal • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53)
    |
    TP53 mutation • KRAS mutation
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    6d
    A single-arm, multicenter, open-label clinical study to evaluate the efficacy and safety of trifluridine/tipiracil combined with tislelizumab and bevacizumab in patients with third-line or later locally advanced unresectable or metastatic colorectal cancer (ChiCTR2500112562)
    P=N/A, N=57, Recruiting, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • Lonsurf (trifluridine/tipiracil)
    6d
    Exploratory clinical study of fuquinitinib combined with TAS-102 as a second-line maintenance therapy for patients with metastatic colorectal cancer (ChiCTR2500112655)
    P4, N=40, Not yet recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital
    New P4 trial
    |
    RAS mutation
    |
    Lonsurf (trifluridine/tipiracil)
    6d
    Trifluridine-Tipiracil plus Fruquintinib vs Trifluridine-Tipiracil plus Bevacizumab for Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority trial (TAS-FUR) (ChiCTR2500112138)
    P4, N=236, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University
    New P4 trial
    |
    RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    6d
    Low-dose trifluridine/tipiracil with bevacizumab in refractory metastatic colorectal cancer: a multicenter, single-arm, phase 2 study (ChiCTR2500115479)
    P2, N=50, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil)
    9d
    A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Anhui Provincial Cancer Hospital
    New trial
    |
    AiTan (rivoceranib) • Lonsurf (trifluridine/tipiracil)
    15d
    A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=464, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P3 trial
    |
    RAS mutation • RAS wild-type
    |
    Lonsurf (trifluridine/tipiracil)
    16d
    ALTAIR: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection (clinicaltrials.gov)
    P3, N=243, Completed, National Cancer Center Hospital East | Recruiting --> Completed
    Trial completion • Circulating tumor DNA
    |
    Signatera™
    |
    Lonsurf (trifluridine/tipiracil)